Ensysce Biosciences, Inc. (ENSC)

0.4811 +0.01 (+1.71%) USD  |  NASDAQ  |  Sep 09, 11:40
More

Ensysce Biosciences EPS Diluted (Quarterly) : -0.1972 for June 30, 2026

EPS Diluted (Quarterly) Chart

View EPS Diluted (Quarterly) for ENSC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EPS Diluted (Quarterly) Chart
Start Trial

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 -0.1972
March 31, 2026 -0.52
December 31, 2025 -0.75
September 30, 2025 -1.292
June 30, 2025 -0.7871
March 31, 2025 -1.389
December 31, 2024 -2.629
September 30, 2024 1.004
June 30, 2024 -3.348
March 31, 2024 -8.210
December 31, 2023 -16.71
September 30, 2023 -13.07
June 30, 2023 -14.75
March 31, 2023 -31.25
December 31, 2022 -273.60
September 30, 2022 -923.69
June 30, 2022 -847.26
March 31, 2022 -219.89
Date Value
December 31, 2021 -1583.57
September 30, 2021 -2547.40
June 30, 2021 -209.81
March 31, 2021 -206.39
December 31, 2020 48.28
September 30, 2020 335.56
June 30, 2020 -160.85
March 31, 2020 1012.32
December 31, 2019 -198.83
September 30, 2019 70.63
June 30, 2019 60.44
March 31, 2019 111.78
December 31, 2018 104.15
September 30, 2018 83.23
June 30, 2018 59.83
March 31, 2018 58.50
December 31, 2017 -21.42
September 30, 2017 -2.88

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. -1.355
Oncolytics Biotech, Inc. -0.0788
Sangamo Therapeutics, Inc. -0.0796
Sarepta Therapeutics, Inc. -0.0464
Anixa Biosciences, Inc. -0.0749

EPS Diluted (Quarterly) Related Metrics

Net Income (Quarterly) -2.571M
Revenue (Quarterly) 1.164M
Total Expenses (Quarterly) 3.735M
Enterprise Value 6.867M
Gross Profit Margin (Quarterly) 99.44%
Profit Margin (Quarterly) -220.8%
Earnings Yield -573.5%
Normalized Earnings Yield -573.60